Aromasin 25 - Aaster Solutions

Exemestane, commercially known as Aromasin, is a steroidal aromatase inhibitor first approved in 1999. It was developed by Pharmacia for treating estrogen-dependent breast cancer in postmenopausal women. Unlike nonsteroidal inhibitors, Exemestane binds irreversibly to the aromatase enzyme, making it a suicide inhibitor. Its action significantly reduces circulating estrogen. Outside oncology, it gained attention in the athletic world for mitigating side effects from anabolic steroids. It is widely distributed globally and usually supplied as 25 mg oral tablets.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Aromasin 25 by Aaster Solutions, consult with your doctor or healthcare professional.